ArticleOpen forum infectious diseases2022

Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial.

Jennifer Sasson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.